|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 25, 2017 ) Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for almost 10% of all hematologic cancers. Immunotherapy is the latest methodology to multiple myeloma treatment. It is an umbrella term that defines different ways to inspire the immune system and improve its capability to attack cancer cells. Chemicals are released by multiplying myeloma plasma cells that consequence in dissolving and damaging of bones.
View Full Report @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-multiple-myeloma-therapeutics-market-863/
Factors such as varied therapeutic areas, rising investment in research and development for new therapies, increasing demand and extensive off-label use of IG are some of the foremost factors contributing to the growth of the multiple myeloma therapeutics market. Stringent regulations and reimbursement issues are the key factors probable to obstruct the multiple myeloma therapeutics market growth.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-multiple-myeloma-therapeutics-market-863/request-sample
The Middle-East and Africa Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-multiple-myeloma-therapeutics-market-863/inquire
Based on geography the market is analysed under various regions namely, Middle-East and Africa. Africa dominates the multiple myeloma therapeutics market while Middle-East is anticipated to grow at highest rate in the forecast period.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
